Andy Orth is the President, Chief Executive Officer, and member of the board of City Therapeutics. Mr. Orth is a seasoned biopharmaceutical leader with over 25 years of experience developing and commercializing novel medicines.

Prior to joining City, Mr. Orth served as Chief Commercial Officer of Krystal Biotech, where he led global commercial strategy, and execution. Previously, he held multiple leadership roles at Alnylam Pharmaceuticals, including Senior Vice President, U.S. Region. In this role, he led Alnylam’s domestic business and launched the first-ever RNAi therapeutic, ONPATTRO®, followed by the launches of GIVLAARI® and OXLUMO®. Before Alnylam, Mr. Orth was on the Global Commercial Strategy and U.S. Business leadership teams at Biogen.

Earlier in his career, Mr. Orth held positions in global commercial strategy, commercial operations, corporate strategy, and finance at Russell Reynolds Associates, Genzyme Corp. (subsequently acquired by Sanofi), and Amgen, and served as a research associate in the Osteoporosis and Arthritis Research Group at the University of California, San Francisco. Mr. Orth received his MBA from the Johnson Graduate School of Management at Cornell University and his undergraduate degree from the University of Wisconsin.